intp58

CDSCO Panel Directs Intas Pharma to Revise Phase I/III Pembrolizumab Trial Protocol We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link